Eli Lilly and Co.'s Trulicity now available

INDIANAPOLIS — Eli Lilly and Co. on Monday announced that its Type 2 diabetes treatment drug Trulicity (dulaglutide) , is now available in U.S. pharmacies. The drug is a once-weekly glucagon-like peptide-1 receptor agonist, and comes in a single-dose pen, which doesn't require the patient to mix, measure or handle the needle, the company said. Trulicity received approval from the Food and Drug Administration in September. 

 

“Some adults with Type 2 diabetes find that diet, exercise and oral medicines aren’t enough to meet their treatment goals,” said Dr. Laura Fernandez, senior medical advisor, Lilly Diabetes. “Trulicity may be an option for them as it has demonstrated proven glycemic control, only has to be taken once weekly, and comes in an easy-to-use pen.”

 

Trulicity is meant to be used as an adjunct to diet and exercise to improve glycemic control in adults who have Type 2 diabets. It is not recommended as a first-line therapy for patients who aren't adequately controlled on diet and exercise, the company said. Trulicity also is not indicated for the treatment of Type 1 diabetes or diabetic ketoacidosis.